because an analysis of in vitro , pharmacokinetic , and clinical data suggested that the combination of rifampicin and tmp ( rifaprim ) would be safe and highly active , an eight-year study of this combination for the treatment of urinary tract infection was done .
C0041041
tmp
C0042029
of urinary tract infection